Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
08. Mai 2023 03:30 ET
|
AKAMPION
- OMN6 demonstrates safety and tolerability at clinically significant dose levels JERUSALEM, Israel, May 8th, 2023 -- Omnix Medical, a biopharmaceutical company developing next-generation...
ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
25. April 2023 04:00 ET
|
AKAMPION
- Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 –...
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
12. April 2023 08:00 ET
|
AKAMPION
Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material...
EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases
03. April 2023 04:00 ET
|
AKAMPION
Presentation at the World Vaccine Congress 2023EBV-infections associated with many cancers and multiple sclerosis Munich, Germany, April 3, 2023 – EBViously, a start-up developing novel vaccines...
InfanDx AG gibt strategische Neuausrichtung und Erweiterung der Diagnostik-Pipeline für Pädiatrie bekannt
28. März 2023 04:00 ET
|
AKAMPION
Eine vertiefte Analyse der vielversprechenden Top-Line-Daten für metabolische Biomarker hat ergeben, dass die Ergebnisse der BANON-Studie nicht allgemein auf HIE-Patienten in der klinischen Routine...
InfanDx AG Revises Strategy and Broadens Diagnostics Pipeline for Child Health
28. März 2023 04:00 ET
|
AKAMPION
After promising top-line data for metabolic biomarkers, in-depth data analysis revealed BANON study results not generalizable to HIE patients in clinical routine.Development of HypoxE® test based...
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
28. März 2023 03:45 ET
|
AKAMPION
- Novel compound for targeted tumor therapy to be evaluated in patients with soft tissue sarcoma- First patients to be enrolled in Q2, 2023 Munich, Germany – March 28, 2023 – Thermosome, a...
HpVac reports positive effects of its lead compound HpVac-R13 in a murine model of allergic asthma following oral administration
27. März 2023 04:00 ET
|
AKAMPION
- Study results indicate beneficial effects on airway hyperresponsiveness, remodeling and inflammation Geneva, Switzerland, March 27, 2023 – HpVac SA, a company developing novel preventive and...
Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
21. März 2023 05:00 ET
|
AKAMPION
- Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 --- Dopavision, a clinical-stage company pioneering the...
Cellbox Solutions Raises EUR 6.5 Million in Series A1 Financing Round
07. März 2023 04:00 ET
|
AKAMPION
- CK Ventures, Fraunhofer Ventures, NRW.Venture and Fil Bros join forces with renowned private investors- Planned expansion of US business and launch of tailored cell therapy shipment solutions ...